Lau Brandon, Kumar Sanjeev, Yan Tristan, Burn Juliet, Kennedy Catherine, McLean Jocelyn, Boyer Michael, McCaughan Brian, Kao Steven
Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Lung Cancer. 2017 Sep;111:75-78. doi: 10.1016/j.lungcan.2017.07.010. Epub 2017 Jul 13.
A small proportion of patients with malignant pleural mesothelioma (MPM) achieve pathological complete response (CR) following treatment with current practice induction chemotherapy. Our analysis of 58 patients with MPM treated with platinum-based chemotherapy showed 4 patients (7%) attained pathological CR at subsequent extrapleural pneumonectomy (EPP). Patient and tumour factors such as age, gender, smoking habit, histological subtype, and clinical stage were not found to be associated with pathological CR. Patients with pathological CR had longer disease-free survival (29.2 vs. 13.8 months; p=0.08) and overall survival (76.4 vs. 23.4 months; p=0.06) but this did not reach statistical significance. Our study suggests that patients who achieve pathological CR after chemotherapy may have improved survival in MPM.
一小部分恶性胸膜间皮瘤（MPM）患者在接受当前常用的诱导化疗后可实现病理完全缓解（CR）。我们对58例接受铂类化疗的MPM患者进行分析，结果显示4例患者（7%）在随后的胸膜外全肺切除术（EPP）中达到了病理CR。未发现年龄、性别、吸烟习惯、组织学亚型和临床分期等患者及肿瘤因素与病理CR相关。病理CR患者的无病生存期（29.2个月对13.8个月；p=0.08）和总生存期（76.4个月对23.4个月；p=0.06）更长，但未达到统计学意义。我们的研究表明，化疗后实现病理CR的患者在MPM中可能有更好的生存情况。
